论文部分内容阅读
目的分析评价孟鲁司特钠联合布地奈德防治儿童哮喘的临床疗效。方法选择2015年10月至2016年11月本院收治的90例哮喘患儿作为研究对象,通过随机信封法将其平均分为对照组(n=45)和实验组(n=45),对照组采用布地奈德治疗;实验组采用孟鲁司特钠联合布地奈德治疗,对比分析两组临床症状消失时间、血清中的炎症因子。结果实验组临床症状消失时间、血清炎症因子明显低于对照组,P<0.05。结论孟鲁司特钠联合布地奈德在防治儿童哮喘中具有较高的临床疗效,降低患儿临床症状消失时间的同时,降低血清中的炎症因子,值得临床推广应用。
Objective To evaluate the clinical efficacy of combination of montelukast and budesonide in the prevention and treatment of childhood asthma. Methods Totally 90 children with asthma admitted to our hospital from October 2015 to November 2016 were selected as the study subjects and randomly divided into control group (n = 45) and experimental group (n = 45) Budesonide treatment group; experimental group with montelukast combined with budesonide treatment, comparative analysis of the disappearance of clinical symptoms of time, serum inflammatory cytokines. Results The disappearance time of clinical symptoms and the serum inflammatory factors in the experimental group were significantly lower than those in the control group (P <0.05). Conclusion Combination of montelukast and budesonide has a higher clinical efficacy in the prevention and treatment of childhood asthma, reducing the disappearance of clinical symptoms in children and reducing the serum inflammatory cytokines, which deserves clinical application.